HORMONE REPLACEMENT THERAPY AND COGNITION IN MENOPAUSAL WOMEN

DR STAMATIOS TZANNINIS
CORE MEDICAL TRAINEE CT1 IN SALISBURY DISTRICT HOSPITAL, FINAL YEAR MSC STUDENT IN THE UNIVERSITY OF EDINBURGH

Hormone Replacement → Therapy = oestrogens alone e.g. 17β-oestradiol, conjugated equine oestrrogen
Or
Progestins alone e.g. micronised progesterone, medroxyprogesterone acetate
Or
A combination of both

MATERIALS AND METHODS

- Online search on Pubmed, Embase and PsycINFO databases
- 51 RCTs were collected

Main selection criteria were:
1. Study type had to be a randomised controlled trial (RCT) in English
2. Subjects should be perimenopausal or menopausal women, aged 40 years or above
3. Hormone replacement therapy should be the intervention studied
4. The end point had to be a measure of cognition e.g. memory, verbal fluency, or the diagnosis or deterioration of dementia of any aetiology or the diagnosis of cognitive impairment of any type

RESULTS

- Only 6 of the included studies showed a positive effect of HRT on specific cognitive measures.
- 45 RCTs showed ineffectiveness or harmful impact
- Large trials like the Women’s Health Initiative showed that HRT increases the risk for dementia and cognitive decline
- Cognitive decrements caused by HRT persist even after stopping it
- Socioeconomic background is an important confounding factor
- Timing of initiation of HRT plays a protagognic role

CONCLUSION

HRT for the prevention or treatment of cognitive impairment in menopausal women is NOT RECOMMENDED